We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

11 hedge funds and large institutions have $32.6M invested in Summit Therapeutics in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 → 11 (0)

0% less ownership

Funds ownership: 2.9% → 2.9% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

23% less capital inflows, than outflows

Capital inflows: $119K | Capital outflows: $155K

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$108K
2
Axa
Axa
France
+$10.4K
3
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services
Florida
+$1.04K

Top Sellers

Rank Fund Capital Flow
1
Granite Point Capital Management
Granite Point Capital Management
Massachusetts
-$104K
2
Sphera Funds Management
Sphera Funds Management
Israel
-$31K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$10.6K
4
UBS Group
UBS Group
Switzerland
-$9K
5
Morgan Stanley
Morgan Stanley
New York
-$21

SMMT Hedge Fund Activity: Q4 2015 in Review

11 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2015, worth a combined $32.6M — up 10% from $29.5M a quarter earlier.

Fund positioning in SMMT was balanced in Q4 2015: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 4 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $108K. The largest seller was Granite Point Capital Management, cutting an estimated $104K.

  • 11 institutional investors held Summit Therapeutics (SMMT) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $32.6M of Summit Therapeutics stock for Q4 2015, up 10% quarter-over-quarter.
  • 1 fund opened new Summit Therapeutics positions in Q4 2015 and 1 closed out, a net change of 0 holders.
  • The largest Summit Therapeutics buyer in Q4 2015 was Point72 Asset Management, an estimated $108K added.
  • The largest Summit Therapeutics seller in Q4 2015 was Granite Point Capital Management, an estimated $104K sold.

Based on aggregated 13F filings for Q4 2015.